STARCOIN GROUP (00399) has announced that on March 25, 2026, the company entered into a memorandum of understanding for strategic cooperation with Huamei Haibo Biotechnology (Chongqing) Co., Ltd. The board of directors believes that signing the MOU represents a strategic opportunity for the group to enhance its technological capabilities and expand its development channels. Through the proposed collaboration, the group will obtain exclusive usage rights to Huamei Haibo's patented cell standards, proprietary technologies, and related technical services. These exclusive rights are expected to strengthen the foundation of the group's research and development, complement its ongoing oral insulin project, and support the group's long-term goal of elevating its position in the biotechnology and healthcare industries. The proposed cooperation is also anticipated to provide potential pathways for the future commercialization, industrialization, and market deployment of advanced cell-related technologies, thereby creating new revenue opportunities for the group. Furthermore, Huamei Haibo has committed to providing ongoing technical support, documentation, and assistance, which will help reduce operational risks and ensure the smooth implementation of the licensed technologies.